Like every person, every tumour is unique. Molecular information and genomic analysis play an increasingly important role in personalising medicine, especially for cancer patients.
Foundation Medicine is a molecular insights company that provides information to physicians and their patients through a deep understanding of the molecular changes that contribute to diseases such as cancer.
Foundation Medicine offers a full suite of comprehensive genomic profiling (CGP) assays to identify the molecular alterations in an individual patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.
In New Zealand, Roche’s pharmaceutical division is the licensed distributor of FoundationOne®CDx and FoundationOne®Liquid for patients with solid tumours, as well as FoundationOne®Heme for patients with sarcomas or haematological cancers including leukaemia, lymphoma and myeloma.
Information for Patients
Cancer treatment has evolved to become as unique as your cancer. Now we have medicines that target unique genomic alterations driving your cancer - so we need to find out which targeted treatment is right for you.
For more information, visit www.mycancerisunique.co.nz and speak with your healthcare professional. Only medical doctors are able to order a Foundation Medicine test.
Healthcare professionals - for information or to place an order
Orders may be placed by medical doctors through www.foundationmedicine.co.nz